L16 Therapeutics of Asthma

Description

PHCY310 Quiz on L16 Therapeutics of Asthma, created by Mer Scott on 12/04/2019.
Mer Scott
Quiz by Mer Scott, updated more than 1 year ago
Mer Scott
Created by Mer Scott about 5 years ago
8
0

Resource summary

Question 1

Question
Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.
Answer
  • True
  • False

Question 2

Question
Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.
Answer
  • True
  • False

Question 3

Question
When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of [blank_start]signs and symptoms[blank_end](wheezing, breathlessness, chest tightness, and coughing, particularly at [blank_start]night[blank_end] or [blank_start]early[blank_end] in the morning). We can also measure [blank_start]expiratory airflow[blank_end] on more than one occasion, and assess [blank_start]response[blank_end] to inhaled bronchodilator +/- inhaled corticosteroid.
Answer
  • signs and symptoms
  • night
  • early
  • expiratory airflow
  • response

Question 4

Question
Ideal PEFR values depend on height and sex.
Answer
  • True
  • False

Question 5

Question
Which of these is NOT a principle of asthma treatment?
Answer
  • Avoid triggers
  • Making an asthma plan
  • Drugs to improve ventilation
  • Drugs to decrease inflammation
  • Avoid exercise

Question 6

Question
Goals of asthma treatment are about maintaining long-term control using the [blank_start]least[blank_end] amount of medications and [blank_start]minimising[blank_end] adverse effects. We want to prevent chronic [blank_start]symptoms[blank_end], require infrequent use ([blank_start]2[blank_end] or fewer days/week) of SABA, maintain normal or near-normal [blank_start]pulmonary[blank_end] function and maintain [blank_start]activity[blank_end] levels. We should assure patients’ and families’ [blank_start]satisfaction[blank_end] with asthma care. We also want to prevent exacerbations, the need for [blank_start]hospitalisation[blank_end], and prevent progressive [blank_start]loss[blank_end] of lung function.
Answer
  • least
  • minimising
  • symptoms
  • 2
  • pulmonary
  • activity
  • satisfaction
  • hospitalisation
  • loss

Question 7

Question
Which of these is not a drug delivery device?
Answer
  • Soft mist inhaler (SMI) - only with LAMA products in NZ
  • Nebuliser
  • Dry power inhaler (DPI)
  • Metered-dose inhaler (MDI) - spacer chamber
  • Dry mist inhaler (DMI)

Question 8

Question
Treatment steps: 1. At initial diagnosis, all patients should use a [blank_start]SABA[blank_end], as required.. 2. Add an [blank_start]ICS[blank_end] if patients have symptoms for more than [blank_start]two[blank_end] weeks. Often a big decision! (The usual dose in adults is [blank_start]budesonide 400 mcg[blank_end]/day.) 3. If control is not adequate, [blank_start]ICS dose[blank_end] can be increased. 4. If control is not adequate, combine [blank_start]ICS with a LABA[blank_end]. ([blank_start]Formoterol+budesonide[blank_end] can be used as a preventer and replace SABA.) Patients can step up or down in order to achieve and maintain control. Check adherence and inhaler [blank_start]technique[blank_end] at each step of the way!
Answer
  • SABA
  • ICS
  • two
  • budesonide 400 mcg
  • ICS dose
  • ICS with a LABA
  • Formoterol+budesonide
  • technique
Show full summary Hide full summary

Similar

Social Psychology - Social Influence
ebramhall
Geography - Unit 1A
NicoleCMB
French -> small but important words for GCSE
georgie_hill
Themes of Jane Eyre
blackfeather1128
Exam 2- High Renaissance/Baroque
Rachel Masingill
Diabetes - pathophysiology
Morgan Morgan
PMP Formulas
Krunk!
Costume History Slidshow
Jemi Armstrong
PreAlgebra End of Year Review
Karla Digmann
Music Therapy Practice Exam (with explanations)
Hannah Rebecca